Narrow search
Showing 1 - 10 of 55
Cover Image
Verteporfin in neovascular amd : real life confirms Clinical trials results
Le Pen, Claude; Sambuc, R.; Soubrane, G.; Quentel, G.; … - Université Paris-Dauphine (Paris IX) - 2009
Persistent link: https://www.econbiz.de/10010861586
Cover Image
Public regulation of the cancer drugs market in French hospitals
Le Pen, Claude; Rieu, C.; Bensadon, M.; … - Université Paris-Dauphine (Paris IX) - 2009
Persistent link: https://www.econbiz.de/10010706533
Cover Image
Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program
Sinègre, Martine; Le Pen, Claude; Parent de Curzon, Olivier - Université Paris-Dauphine (Paris IX) - 2011
Persistent link: https://www.econbiz.de/10010708345
Cover Image
Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra)
Le Pen, Claude; Miadi-Fargier, H.; Fautrel, B.; Maravic, M. - Université Paris-Dauphine (Paris IX) - 2008
Persistent link: https://www.econbiz.de/10010708384
Cover Image
Political Contributions to Influence Consumers: the Example of the U.S. Drug Reimportation Debate
Boring, Anne - Université Paris-Dauphine (Paris IX) - 2010
Persistent link: https://www.econbiz.de/10010708442
Cover Image
Does pharmaceutical consumption improve health care Status ?
Amalric, F.; Hauser, S.; Grandfils, N.; Le Pen, Claude - Université Paris-Dauphine (Paris IX) - 2009
Persistent link: https://www.econbiz.de/10010708719
Cover Image
(De)construction of pharmaceutical industry reputation through material practices regulation
Lambrix, Hélène - Université Paris-Dauphine (Paris IX) - 2014
In this empirical paper, I am looking at how individuals make reputational judgement of pharmaceutical companies when they prescribe a medicine, and, how the Mediator’s scandal in France has changed rules, material practices and the institutional logic. The literature review explores first the...
Persistent link: https://www.econbiz.de/10011074408
Cover Image
External referencing and pharmaceutical price negociation
Garcia Marinoso, Begona; Jelovac, Izabella; Olivella, Pau - Université Paris-Dauphine (Paris IX) - 2011
External referencing (ER) imposes a price cap for pharmaceuticals, based on prices of identical or comparable products …
Persistent link: https://www.econbiz.de/10010707663
Cover Image
Determinants of the United States’ trade of pharmaceuticals
Boring, Anne - Université Paris-Dauphine (Paris IX) - 2010
pharmaceuticals in developing countries and should increase trade. The industry argues that other factors are necessary for poor … the United States’ trade of pharmaceuticals? A gravity model using panel data from 1993 to 2007 shows that foreign patent … protection is not a strong determinant of the United States imports and exports of pharmaceuticals. An OLS estimation, a Tobit …
Persistent link: https://www.econbiz.de/10010708922
Cover Image
The Certification Role of Listings
Draus, Sarah - Université Paris-Dauphine (Paris IX) - 2009
I propose a model in which firms can convey their quality by listing on a stock exchange. To list, firms must comply with costly listing requirements allowing investors to recognize imperfectly their quality. A profit maximizing exchange may set listing requirements leading to high information...
Persistent link: https://www.econbiz.de/10010861490